Kuria Therapeutics and SCOHIA PHARMA Announce Strategic Licensing Agreement for Ophthalmic and Dermal Rights to SCO-116, A Novel Nrf2 Activator
– Kuria is granted exclusive worldwide rights to develop, manufacture, and commercialize asset for ocular and dermatologic diseases with localized therapeutic application; SCOHIA PHARMA to receive upfront payment plus up to 67 million USD in potential regulatory, development, and commercial milestones KANAGAWA, Japan & LITTLE ROCK, Ark.–(BUSINESS WIRE)–Kuria Therapeutics, Inc., a US pharmaceutical company developing … [Read more…]
